Search - tctmd.com

Displaying 1 - 20 of 42

Sort: Relevancy | Date

Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Presentation JIM 2016

The COMBO dual therapy stent: From the REMEDEE registry to the REDUCE trial

Presenter: Giuseppe De Luca

February 10, 2016

Presentation

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Presenter: Dean J. Kereiakes

October 22, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Presenter: F. Costa

August 21, 2015

Presentation

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Presenter: T. Palmerini

March 18, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Presenter: Jun-Hyok Oh

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Advertisement

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

The COMBO dual therapy stent: From the REMEDEE registry to the REDUCE trial

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content